UCB raised 2026 outlook as UCB stock trades at EUR 268.00

Published on 10/27/2026 at 11:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB expects revenue growth in the low twenties for 2026 at constant exchange rates. UCB stock costs EUR 268.00 in trading on October 27, 2026.

Growth guidance and key date

UCB announced its second 2026 guidance upgrade on October 22, 2026.
Revenue growth is expected in the low twenties at constant exchange rates.
UCB stock trades at EUR 268.00 at 11:16 a.m. CEST at Lang & Schwarz on October 27, 2026.
Full-year 2026 results are scheduled for February 25, 2027.

UCB, BE0003739530, Illustration mit AI erstellt.

UCB stock (ISIN BE0003739530) was trading at EUR 268.00 at Lang & Schwarz on October 27, 2026 at 11:16 a.m. CEST, while UCB had raised its 2026 financial guidance on October 22. The company now expects revenue growth in the low twenties at constant exchange rates, compared with its previous low-to-mid-teens outlook, according to UCB.

UCB raises the growth bar

The upgrade was UCB's second guidance increase in 2026. Adjusted EBITDA growth is now expected in the low-to-mid-forties at constant exchange rates, up from the previous mid-teens to low-twenties range.

The company attributed the change to stronger BIMZELX performance in the United States, supported by patient demand, improved access and favorable net pricing. CIMZIA also contributed through volume growth and improved pricing despite a contracting anti-TNF market, UCB said in its October 22 release.

What does the outlook mean?

The guidance points to operating leverage because the adjusted EBITDA growth range is higher than the revenue growth range. The outlook excludes proceeds from a Priority Review Voucher, which UCB said could add low-to-mid-single-digit percentage points to revenue and adjusted EBITDA growth.

For context, UCB reported revenue of EUR 7.7 billion in fiscal year 2025 and employs more than 9,000 people, according to the same company release. The latest investor materials also show BIMZELX sales of EUR 1.52 billion in the first half of 2026, while FINTEPLA sales reached EUR 239 million in that period.

Analyst target points higher

AlphaValue/Baader Europe downgraded UCB from accumulate to reduce while raising its price target from EUR 260.00 to EUR 267.00 in a note dated October 27, 2026, according to Zonebourse. That combination puts the analyst view below the Lang & Schwarz price and highlights valuation as a counterweight to the stronger operating outlook.

Next reporting date

UCB will publish its full-year 2026 results and formal 2027 guidance on February 25, 2027, according to the company's October 22 release.

Stock and guidance in view

UCB stock was trading at EUR 268.00 at Lang & Schwarz on October 27, 2026 at 11:16 a.m. CEST. The market capitalization was EUR 51.2 billion, and the 52-week range was EUR 197.45 to EUR 289.50 as of October 27, 2026.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.